GlassScriptPhysician profile
Kevin D Clark
NPI 1447366976
$4,978.56
in general payments reported to CMS, 2019-2025
25 companies · $222 in 2025
The $222 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,175 · 2020: $349 · 2021: $318 · 2022: $711 · 2023: $204 · 2025: $222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $425.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,939.01 | 2019-2023 | Rocklatan, Hydrus Microstent |
| Allergan, INC. | $531.51 | 2019-2021 | |
| Coopervision INC. | $511.03 | 2019 | |
| Carl Zeiss Meditec, INC. | $344.41 | 2019-2021 | |
| Ivantis, INC | $245.14 | 2019-2021 | |
| Kestra Medical Technology Services, INC. | $221.59 | 2025 | Assure Wcd |
| New World Medical,INC. | $184.95 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $136.44 | 2022-2023 | Cequa |
| Shire North American Group INC | $110.62 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $101.66 | 2022 | |
| Abbvie INC. | $96.86 | 2022-2023 | Alphagan P, Lumigan, Vuity |
| Biotissue Holdings INC. | $85.30 | 2022 | |
| Oyster Point Pharma, INC. | $66.93 | 2022-2023 | Tyrvaya |
| Carl Zeiss Meditec USA, INC. | $59.56 | 2022 | |
| Mallinckrodt Hospital Products INC. | $58.41 | 2022-2023 | Acthar |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $52.17 | 2019-2021 | |
| Horizon Therapeutics Plc | $46.74 | 2022-2023 | Tepezza |
| Rxsight INC | $40.76 | 2022 | |
| Bausch & Lomb Americas INC. | $34.67 | 2022 | |
| Novartis Pharmaceuticals Corporation | $22.50 | 2022 | |
| Travere Therapeutics, INC. | $21.08 | 2023 | Cholbam |
| Dompe US, INC. | $19.54 | 2022 | |
| Abb Con-Cise Optical Group LLC | $17.66 | 2019 | |
| Mallinckrodt Enterprises LLC | $16.38 | 2019 | |
| Musculoskeletal Transplant Foundation INC. | $13.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.